Rare Diseases: Clinical Trials

Department of Health and Social Care written question – answered on 10th March 2020.

Alert me about debates like this

Photo of Stephen Morgan Stephen Morgan Shadow Minister for Local Government (Communities), Shadow Minister (Defence) (Armed Forces and Defence Procurement), Shadow Minister (Defence)

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effect of the UK leaving the EU on the future success of clinical trials for personalised medicines for the treatment of rare diseases.

Photo of Helen Whately Helen Whately Minister of State (Department of Health and Social Care)

The United Kingdom is one of the best places in the world to undertake clinical trials due to our world-class regulatory environment, universal National Health Service, vibrant universities and our levels of investment in research from the Government, charities and the life sciences industry.

Now we have left the European Union, we will build on our thriving clinical trials ecosystem, including for personalised medicines and rare diseases. The newly introduced Medicines and Medical Devices Bill sets out a package of revolutionary measures to get cutting-edge, personalised treatment to patients as soon as possible, demonstrating the UK’s commitment to remain a world-leader in clinical trials and innovation. More information on the Bill can be found at the following link:

https://services.parliament.uk/Bills/2019-20/medicinesandmedicaldevices.html

Does this answer the above question?

Yes2 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.